Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 94

1.

Trajectories of change in depression severity during treatment with antidepressants.

Uher R, Muthén B, Souery D, Mors O, Jaracz J, Placentino A, Petrovic A, Zobel A, Henigsberg N, Rietschel M, Aitchison KJ, Farmer A, McGuffin P.

Psychol Med. 2010 Aug;40(8):1367-77. doi: 10.1017/S0033291709991528. Epub 2009 Oct 29.

PMID:
19863842
2.

Melancholic, atypical and anxious depression subtypes and outcome of treatment with escitalopram and nortriptyline.

Uher R, Dernovsek MZ, Mors O, Hauser J, Souery D, Zobel A, Maier W, Henigsberg N, Kalember P, Rietschel M, Placentino A, Mendlewicz J, Aitchison KJ, McGuffin P, Farmer A.

J Affect Disord. 2011 Jul;132(1-2):112-20. doi: 10.1016/j.jad.2011.02.014. Epub 2011 Mar 15.

PMID:
21411156
3.

Genome-wide pharmacogenetics of antidepressant response in the GENDEP project.

Uher R, Perroud N, Ng MY, Hauser J, Henigsberg N, Maier W, Mors O, Placentino A, Rietschel M, Souery D, Zagar T, Czerski PM, Jerman B, Larsen ER, Schulze TG, Zobel A, Cohen-Woods S, Pirlo K, Butler AW, Muglia P, Barnes MR, Lathrop M, Farmer A, Breen G, Aitchison KJ, Craig I, Lewis CM, McGuffin P.

Am J Psychiatry. 2010 May;167(5):555-64. doi: 10.1176/appi.ajp.2009.09070932. Epub 2010 Apr 1.

PMID:
20360315
4.

Early and delayed onset of response to antidepressants in individual trajectories of change during treatment of major depression: a secondary analysis of data from the Genome-Based Therapeutic Drugs for Depression (GENDEP) study.

Uher R, Mors O, Rietschel M, Rajewska-Rager A, Petrovic A, Zobel A, Henigsberg N, Mendlewicz J, Aitchison KJ, Farmer A, McGuffin P.

J Clin Psychiatry. 2011 Nov;72(11):1478-84. doi: 10.4088/JCP.10m06419.

5.

Convergent animal and human evidence suggests a role of PPM1A gene in response to antidepressants.

Malki K, Uher R, Paya-Cano J, Binder E, Rietschel M, Zobel A, Mors O, Hauser J, Henigsberg N, Jerman B, Souery D, Placentino A, Ng MY, Cohen-Woods S, Sluyter F, Farmer A, Aitchison KJ, Craig IW, Lewis CM, McGuffin P, Schalkwyk LC.

Biol Psychiatry. 2011 Feb 15;69(4):360-5. doi: 10.1016/j.biopsych.2010.08.011. Epub 2010 Oct 20.

PMID:
20970119
6.

Differential efficacy of escitalopram and nortriptyline on dimensional measures of depression.

Uher R, Maier W, Hauser J, Marusic A, Schmael C, Mors O, Henigsberg N, Souery D, Placentino A, Rietschel M, Zobel A, Dmitrzak-Weglarz M, Petrovic A, Jorgensen L, Kalember P, Giovannini C, Barreto M, Elkin A, Landau S, Farmer A, Aitchison KJ, McGuffin P.

Br J Psychiatry. 2009 Mar;194(3):252-9. doi: 10.1192/bjp.bp.108.057554. Erratum in: Br J Psychiatry. 2009 Jul;195(1):87.

7.

Genetic predictors of response to antidepressants in the GENDEP project.

Uher R, Huezo-Diaz P, Perroud N, Smith R, Rietschel M, Mors O, Hauser J, Maier W, Kozel D, Henigsberg N, Barreto M, Placentino A, Dernovsek MZ, Schulze TG, Kalember P, Zobel A, Czerski PM, Larsen ER, Souery D, Giovannini C, Gray JM, Lewis CM, Farmer A, Aitchison KJ, McGuffin P, Craig I.

Pharmacogenomics J. 2009 Aug;9(4):225-33. doi: 10.1038/tpj.2009.12. Epub 2009 Apr 14.

PMID:
19365399
8.

Duloxetine versus escitalopram and placebo in the treatment of patients with major depressive disorder: onset of antidepressant action, a non-inferiority study.

Nierenberg AA, Greist JH, Mallinckrodt CH, Prakash A, Sambunaris A, Tollefson GD, Wohlreich MM.

Curr Med Res Opin. 2007 Feb;23(2):401-16.

PMID:
17288694
9.

An inflammatory biomarker as a differential predictor of outcome of depression treatment with escitalopram and nortriptyline.

Uher R, Tansey KE, Dew T, Maier W, Mors O, Hauser J, Dernovsek MZ, Henigsberg N, Souery D, Farmer A, McGuffin P.

Am J Psychiatry. 2014 Dec 1;171(12):1278-86. doi: 10.1176/appi.ajp.2014.14010094. Epub 2014 Oct 31.

PMID:
25017001
10.

Suicidal ideation during treatment of depression with escitalopram and nortriptyline in genome-based therapeutic drugs for depression (GENDEP): a clinical trial.

Perroud N, Uher R, Marusic A, Rietschel M, Mors O, Henigsberg N, Hauser J, Maier W, Souery D, Placentino A, Szczepankiewicz A, Jorgensen L, Strohmaier J, Zobel A, Giovannini C, Elkin A, Gunasinghe C, Gray J, Campbell D, Gupta B, Farmer AE, McGuffin P, Aitchison KJ.

BMC Med. 2009 Oct 15;7:60. doi: 10.1186/1741-7015-7-60.

11.

S-adenosyl methionine (SAMe) for depression in adults.

Galizia I, Oldani L, Macritchie K, Amari E, Dougall D, Jones TN, Lam RW, Massei GJ, Yatham LN, Young AH.

Cochrane Database Syst Rev. 2016 Oct 10;10:CD011286. Review.

PMID:
27727432
12.

Non-random dropout and the relative efficacy of escitalopram and nortriptyline in treating major depressive disorder.

Power RA, Muthén B, Henigsberg N, Mors O, Placentino A, Mendlewicz J, Maier W, McGuffin P, Lewis CM, Uher R.

J Psychiatr Res. 2012 Oct;46(10):1333-8. doi: 10.1016/j.jpsychires.2012.06.014. Epub 2012 Jul 6.

PMID:
22770672
13.

Variation in GNB3 predicts response and adverse reactions to antidepressants.

Keers R, Bonvicini C, Scassellati C, Uher R, Placentino A, Giovannini C, Rietschel M, Henigsberg N, Kozel D, Mors O, Maier W, Hauser J, Souery D, Mendlewicz J, Schmäl C, Zobel A, Larsen ER, Szczepankiewicz A, Kovacic Z, Elkin A, Craig I, McGuffin P, Farmer AE, Aitchison KJ, Gennarelli M.

J Psychopharmacol. 2011 Jul;25(7):867-74. doi: 10.1177/0269881110376683. Epub 2010 Sep 8.

PMID:
20826553
14.

Escitalopram versus other antidepressive agents for depression.

Cipriani A, Santilli C, Furukawa TA, Signoretti A, Nakagawa A, McGuire H, Churchill R, Barbui C.

Cochrane Database Syst Rev. 2009 Apr 15;(2):CD006532. doi: 10.1002/14651858.CD006532.pub2. Review.

15.

[Escitalopram is more effective than citalopram for the treatment of severe major depressive disorder].

Azorin JM, Llorca PM, Despiegel N, Verpillat P.

Encephale. 2004 Mar-Apr;30(2):158-66. French.

PMID:
15107719
16.

Depression Subtypes in Predicting Antidepressant Response: A Report From the iSPOT-D Trial.

Arnow BA, Blasey C, Williams LM, Palmer DM, Rekshan W, Schatzberg AF, Etkin A, Kulkarni J, Luther JF, Rush AJ.

Am J Psychiatry. 2015 Aug 1;172(8):743-50. doi: 10.1176/appi.ajp.2015.14020181. Epub 2015 Mar 27.

PMID:
25815419
17.

Randomized comparison of selective serotonin reuptake inhibitor (escitalopram) monotherapy and antidepressant combination pharmacotherapy for major depressive disorder with melancholic features: a CO-MED report.

Bobo WV, Chen H, Trivedi MH, Stewart JW, Nierenberg AA, Fava M, Kurian BT, Warden D, Morris DW, Luther JF, Husain MM, Cook IA, Lesser IM, Kornstein SG, Wisniewski SR, Rush AJ, Shelton RC.

J Affect Disord. 2011 Oct;133(3):467-76. doi: 10.1016/j.jad.2011.04.032. Epub 2011 May 23.

PMID:
21601287
18.

Baseline severity of depression predicts antidepressant drug response relative to escitalopram.

Kilts CD, Wade AG, Andersen HF, Schlaepfer TE.

Expert Opin Pharmacother. 2009 Apr;10(6):927-36. doi: 10.1517/14656560902849258 .

PMID:
19317630
19.

Depression symptom dimensions as predictors of antidepressant treatment outcome: replicable evidence for interest-activity symptoms.

Uher R, Perlis RH, Henigsberg N, Zobel A, Rietschel M, Mors O, Hauser J, Dernovsek MZ, Souery D, Bajs M, Maier W, Aitchison KJ, Farmer A, McGuffin P.

Psychol Med. 2012 May;42(5):967-80. doi: 10.1017/S0033291711001905. Epub 2011 Sep 20.

20.

Highly polygenic architecture of antidepressant treatment response: Comparative analysis of SSRI and NRI treatment in an animal model of depression.

Malki K, Tosto MG, Mouriño-Talín H, Rodríguez-Lorenzo S, Pain O, Jumhaboy I, Liu T, Parpas P, Newman S, Malykh A, Carboni L, Uher R, McGuffin P, Schalkwyk LC, Bryson K, Herbster M.

Am J Med Genet B Neuropsychiatr Genet. 2017 Apr;174(3):235-250. doi: 10.1002/ajmg.b.32494. Epub 2016 Oct 1.

Supplemental Content

Support Center